Factor Xa and VIIa inhibition by tissue factor pathway inhibitor is prevented by a monoclonal antibody to its Kunitz-1 domain.
Augustsson, C., Svensson, A., Kjaer, B., Chao, T.Y., Wenjuan, X., Krogh, B.O., Breinholt, J., Clausen, J.T., Hilden, I., Petersen, H.H., Petersen, L.C.(2018) J Thromb Haemost 16: 893-904
- PubMed: 29532595 
- DOI: https://doi.org/10.1111/jth.14000
- Primary Citation of Related Structures:  
5NMV - PubMed Abstract: 
Essentials Activated FVII (FVIIa) and FX (FXa) are inhibited by tissue factor pathway inhibitor (TFPI). A monoclonal antibody, mAb2F22, was raised against the N-terminal fragment of TFPI (1-79). mAb2F22 bound exclusively to the K1 domain of TFPI (K D ∼1 nm) and not to the K2 domain. mAb2F22 interfered with inhibition of both FVIIa and FXa activities and restored clot formation.
Organizational Affiliation: 
Global Research, Novo Nordisk A/S, Måløv, Denmark.